Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 890 participants.
Also called NCT07201688
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 890 participants
- Registry
-
NCT07201688
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07201688. Randomized; triple masking; primary purpose treatment. Start 2025-11-30 (actual); primary completion 2027-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
- Acronym
- TRACE-LATE
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- rhTNK-tPA
- Intervention (Drug)
- Placebo
- Lead sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Record details
- Record id
cardio:ct-nct07201688- Content hash
f948ce09702b4ca008304e9db2f917d5a6a004f3a9d4ac474a033eefacd46a94